Tsvetelina Pencheva Hoang

Tsvetelina Pencheva Hoang has extensive experience in the field of research and development. Tsvetelina most recently served as the Vice President of Research and Development at Marker Therapeutics, Inc. from October 2018 onwards. Prior to that, they held the same role at TapImmune Inc from July 2018 to October 2018. Tsvetelina also worked at Bellicum Pharmaceuticals, Inc. as the Director of Translational Research from December 2015 to July 2018, and as a Senior Scientist from February 2015 to December 2015. Before that, they were an Instructor at MD Anderson Cancer Center from January 2013 to January 2015. Tsvetelina began their career as a Research Associate at Memorial Sloan-Kettering Cancer Center in July 2004 and held that position until December 2012. Tsvetelina also worked as an HHMI research associate at UC-Berkeley from July 2001 to July 2004.

Tsvetelina Pencheva Hoang holds a Doctor of Philosophy (PhD) degree in Biology from The Johns Hopkins University, which they completed between 1996 and 2001. Prior to that, from 1992 to 1996, they pursued a combined BS/MS degree in MB&B at Yale University.